Table 3. Brief description of patients with nodal metastasis falsely classified as low risk.

Characteristics	Patient 1	Patient 2	Patient 3	Patient 4
Preoperative assessment
Age, years	62	47	46	32
FIGO stage	IB1	IB1	IB1	IB1
Histology	Squamous	Squamous	Squamous	Squamous
Serum SCC Ag (ng ml−1)	0.83	0.35	1.4	0.9
Tumour size by MRI (cm)	2	0a	0a	0a
PM invasion by MRI	Absent	Absent	Absent	Absent
LNM by PET/CT	Absent	Absent	Absent	Absent
Postoperative assessment
Histology	Squamous	Squamous	Squamous	Squamous
Tumour size (cm)	4.0	1.5	1.5	1.3
Depth of stromal invasion (mm)	6	2	10	6
LVSI	Present	Absent	Present	Present
PM invasion	Present	Absent	Absent	Absent
LNM	Yes (1 of 34)	Yes (1 of 25)	Yes (1 of 18)	Yes (4 of 42)
Location of metastatic LN	Left external	Right external	Right internal	Left obturator Right external
Largest diameter of metastatic LN	0.7 mm	6 mm	<1 mm	7 mm
Para-aortic LNM	No (0 of 1)	NA	No (0 of 1)	No (0 of 1)
Adjuvant treatment	CCRTb	CCRTb	CCRTb	CCRTb
Recurrence	No	No	No	No
Progression-free survival	21 months	32 months	6 months	40 months

Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; LN=lymph node; LNM=LN metastasis; LVSI=lymphovascular space invasion; MRI=magnetic resonance imaging; NA, not applicable; PET/CT=positron emission tomography/computed tomography; PM=parametrial; SCC Ag=squamous cell carcinoma antigen.

^aNo visible residual tumour in the uterine cervix.

^bConcurrent chemoradiation (weekly cisplatin regimen).